

CLAIMS

We claim:

- 6520072016000
1. A method of diagnosing individuals at risk for a disease state comprising
 - a) determining the distribution of Rad51 foci in a first tissue type of a first individual; and
 - b) comparing said distribution to the distribution of Rad51 foci from a second normal tissue type from said first individual or a second unaffected individual; wherein a difference in said distributions indicates that the first individual is at risk for a disease state which results in aberrant Rad51 loci.
 - 10 2. A method according to claim 1 wherein said disease state is cancer.
 3. A method of diagnosing individuals at risk for cancer comprising
 - a) determining the distribution of Rad51 foci in a potential cancerous tissue type of a first individual; and
 - b) comparing said distribution to the distribution of Rad51 foci from a second normal tissue type from said first individual or a second unaffected individual; wherein a difference in said distributions indicates that the first individual is at risk for a cancer which results in aberrant Rad51 loci.
 - 15 4. A method according to claim 3 wherein the cancer is selected from breast cancer and skin cancer.
 - 20 5. A method of diagnosing individuals at risk for a disease state associated with apoptosis, said method comprising
 - a) determining the distribution of Rad51 foci in a first tissue type of a first individual; and
 - b) comparing said distribution to the distribution of Rad51 foci from a second normal tissue type from said first individual or a second unaffected individual; wherein a difference in said distributions indicates that the first individual is at risk for a disease state associated with apoptosis which results in aberrant Rad51 loci.

- 60
6. A method according to claim 1 wherein the extent of aberrant distribution indicates the severity of the disease state.
7. A method according to claim 1 wherein said distribution is determined through the use of polyclonal antibodies.
- 5 8. A method according to claim 1 wherein said distribution is determined through the use of monoclonal antibodies.
9. A method according to claim 7 or 8 wherein said antibodies are raised against eukaryotic Rad51.
10. A method according to claim 9 wherein said eukaryotic Rad51 is mammalian Rad51. *
11. A method for identifying an apoptotic cell comprising
a) determining the distribution of Rad51 foci in a first cell; and
b) comparing said distribution to the distribution of Rad51 foci from a second non-apoptotic cell;
- 15 wherein a difference in said distributions indicates that the first cell is apoptotic.
12. A method according to claim 11 wherein said distribution is the association of Rad51 with DNA fibers.
13. A method according to claim 11 wherein said distribution is the association of Rad51 into micronuclei.
- 20 14. A method for identifying a cell under stress associated with nucleic acid modification comprising
a) determining the distribution of Rad51 foci in a first cell; and
b) comparing said distribution to the distribution of Rad51 foci from a second non-affected cell;

wherein a difference in said distributions indicates that the first cell is under stress associated with nucleic acid modification.

15. A method according to claim 14 wherein said stress is oxidative or hypoxic stress.

5 16. A method according to claim 14 wherein said stress is heat shock.

17. A method according to claim 14 wherein said stress is cold shock.

18. A method for identifying a cell containing a mutant Rad51 gene comprising determining the sequence of all/or part of at least one of the endogenous Rad51 genes.

10 19. A method of identifying the Rad51 genotype of an individual comprising determining all or part of the sequence of at least one Rad51 gene of said individual.

20. A method according to claim 18 or 19 further comprising comparing the sequence of said Rad51 gene to a known Rad51 gene.

15 21. A method according to claim 20 wherein a difference in the sequence between the Rad51 gene of said individual and said known Rad51 gene is indicative of a disease state or a propensity for a disease state.

22. A method for screening for a bioactive agent capable of binding to Rad51 comprising:

a) adding a candidate bioactive agent to a sample of Rad51; and

20 b) determining the binding of said candidate agent to said Rad51.

23. A method for screening for a bioactive agent capable of modulating the activity of Rad51, said method comprising the steps of:

a) adding a candidate bioactive agent to a sample of Rad51; and

b) determining an alteration in the biological activity of Rad51.

24. A method according to claim 23 wherein said biological activity is DNA dependent ATPase activity.
25. A method according to claim 23 wherein said biological activity is nucleic acid strand exchange.
26. A method according to claim 23 wherein said biological activity is DNA binding.
27. A method according to claim 23 wherein said biological activity is filament formation.
- 10 28. A method according to claim 23 wherein said biological activity is DNA pairing.
29. A method for screening for a bioactive agent capable of modulating the activity of Rad51, said method comprising the steps of:
- 15 a) adding a candidate bioactive agent to a cell; and
- b) determining the effect on the formation or distribution of Rad51 foci in said cell.
30. A method according to claim 25 further comprising subjecting said cell to conditions which induce nucleic acid damage.
31. A method of inducing apoptosis in a cell comprising increasing the activity of Rad51 in said cell.
- 20 32. A method according to claim 31 wherein said increasing comprises overexpression of endogenous Rad51.

33. A method according to claim 31 wherein said increasing comprises administration of a gene encoding Rad51.
34. A method according to claim 31 wherein said increasing comprises administration of Rad51 protein.
- 5 35. A method according to claim 31 wherein said cell is a cancer cell.
36. A method according to claim 31 further comprising subjecting said cell to conditions which induce nucleic acid damage.
37. A method according to claim 36 wherein said conditions comprise the administration of a chemical agent which causes nucleic acid damage.
- 10 38. A method according to claim 36 wherein said conditions comprise subjecting said cell to radiation.
39. A method according to claim 31 further comprising increasing the activity of p53 in said cell.
40. A composition comprising:
a) nucleic acid encoding a Rad51 protein; and
b) nucleic acid encoding a tumor suppressor protein.
- 15 41. A composition according to claim 38 wherein said tumor suppressor protein is p53.
42. A composition according to claim 38 wherein said tumor suppressor protein is 20 BRCA1.
43. A composition according to claim 38 wherein said tumor suppressor protein is BRCA2.

44. A composition according to claim 38 comprising:

- a) nucleic acid encoding a Rad51 protein;
- b) nucleic acid encoding a BRCA1 protein;
- c) nucleic acid encoding a BRCA2 protein; and
- d) nucleic acid encoding a p53 protein.

5

45. A composition comprising:

- a) a recombinant Rad51 protein; and
- b) a recombinant tumor suppressor protein.

46. A kit for detecting the distribution of Rad51 foci in a cell or tissue comprising:

- 10
- a) binding agent for Rad51 foci; and
 - b) a detectable label.

115er
94 >

THIS PAGE BLANK (USPTO)